A new study published in the Journal of Psychopharmacology is the first to characterize the psychological impacts of psilocybin among people with bipolar disorder.
The findings indicate that many people with bipolar disorder who consume psilocybin, the primary psychoactive component of psychedelic “magic mushrooms,” believe that the experience is helpful. However, many also report adverse outcomes, such as manic symptoms.
Read more
Jules Evans of The Challenging Psychedelic Experiences Project discusses the project and what he and his co-researchers hope to learn from the data they collect.
Read more
"Aha” moments in psychedelic therapy can offer unique insight and perspective. But some insights are false and others may ring true.
Read more
Check out this podcast from Psychedelics Today~~ with New York Times best-selling author, pioneer in the field of integrative medicine, and overall legend in the health and wellness space: Andrew Weil, M.D.
Read more
As The New Republic reports, the Colorado-based psychedelics startup Medicinal Mindfulness is currently seeking approval from the Food and Drug Administration to study what it's calling DMTx, an extended-state, intravenous drip version of DMT that will induce in users trips far longer than the roughly five-to-ten minute experiences the drug typically provides.
DMT carries with it a ton of intriguing qualities, including that studies suggest our brains produce the drug naturally and that those who have taken it often experience variations on the same theme: entering what seems to be another plane or dimension replete with its own ethereal beings, sometimes referred to as "machine elves," who are there to welcome them.
Read more
Here’s the official statement from MAPS!
The results confirmed findings from MAPP1; no serious adverse events were observed among the participants
In a first for psychedelic-assisted therapy trials, more than half of MAPP2 participants identify as people of color
Read more